Understand the source comparison
SS-31 Cardioprotection Research: Model Comparison
Rat I/R injury (30 min ischemia) 27–35% vs control LVEF +12% at 1 week Acute (24–168 hours) Strongest evidence; reproducible across labs Porcine I/R injury (90 min ischemia) 22% vs control Preserved regional wall motion Acute (7 days) Clinically relevant anato
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Rat I/R injury (30 min ischemia)
- 27–35% vs control
- LVEF +12% at 1 week
- Acute (24–168 hours)
- Strongest evidence; reproducible across labs
- Porcine I/R injury (90 min ischemia)
- 22% vs control
- Preserved regional wall motion
- Acute (7 days)
- Clinically relevant anatomy; supports translatability
- Mouse pressure-overload HF
- Not applicable
- Fractional shortening 42% vs 28%
- Chronic (4 weeks)
- Demonstrates chronic benefit beyond acute events
- Doxorubicin cardiotoxicity (mouse)
- Prevented 40% LVEF drop
- Chronic (6 weeks)
- Cardioprotection without reducing anti-tumor effect
- The consistency across models is notable. Whether the insult is ischemic, mechanical, or chemical, SS-31's ability to preserve mitochondrial structure translates to measurable cardiac function preservation. This isn't a compound that works in one narrow experimental paradigm and fails when conditions change.